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Pancreatic cancer-associated gene 
polymorphisms in a nation-wide cohort 
of p16-Leiden germline mutation carriers; a 
case–control study
Thomas P Potjer1*, Nienke van der Stoep1, Jeanine J Houwing‑Duistermaat2, Ingrid C A W Konings3, 
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Abstract 
Background: The p16‑Leiden founder mutation in the CDKN2A gene is the most common cause of Familial Atypical 
Multiple Mole Melanoma (FAMMM) syndrome in the Netherlands. Individuals with this mutation are at increased risk 
for developing melanoma of the skin, as well as pancreatic cancer. However, there is a notable interfamilial variabil‑
ity in the occurrence of pancreatic cancer among p16‑Leiden families. We aimed to test whether previously identi‑
fied genetic risk factors for pancreatic cancer modify the risk for pancreatic cancer in p16‑Leiden germline mutation 
carriers.
Methods: Seven pancreatic cancer‑associated SNPs were selected from the literature and were genotyped in a 
cohort of 185 p16‑Leiden germline mutation carriers from 88 families, including 50 cases (median age 55 years) with 
pancreatic cancer and 135 controls (median age 64 years) without pancreatic cancer. Allelic odds ratios per SNP were 
calculated.
Results: No significant association with pancreatic cancer was found for any of the seven SNPs.
Conclusions: Since genetic modifiers for developing melanoma have already been identified in CDKN2A mutation 
carriers, this study does not exclude that genetic modifiers do not play a role in the individual pancreatic cancer risk 
in this cohort of p16‑Leiden germline mutation carriers. The search for these modifiers should therefore continue, 
because they can potentially facilitate more targeted pancreatic surveillance programs.
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Background
The melanoma gene CDKN2A produces two important 
proteins: p16INK4a, which is a cyclin-dependent kinase 
inhibitor, and p14ARF, which binds the p53-stabilizing 
protein MDM2 [1]. In the Netherlands, a founder muta-
tion in the CDKN2A gene, a 19-base pair deletion called 
p16-Leiden (c.225_243del19; RefSeq NM_000077.4), is 
the most common cause of Familial Atypical Multiple 
Mole Melanoma (FAMMM) syndrome [2]. In addition 
to a marked increased risk of developing melanoma of 
the skin (70% lifetime risk), these mutation carriers also 
have a 15–20% lifetime risk of developing pancreatic can-
cer with a mean age of 58  years at diagnosis [3]. Inter-
estingly, there is a notable interfamilial variability in the 
occurrence of pancreatic cancer among p16-Leiden fami-
lies [3]. Therefore, the p16-Leiden mutation might not be 
the only genetic risk factor in these individuals causing 
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an increased susceptibility for pancreatic cancer. Since 
pancreatic cancer has a very poor prognosis due to late 
occurrence of symptoms and therefore late detection, 
surveillance for pancreatic cancer is currently offered to 
p16-Leiden germline mutation carriers in a research set-
ting to investigate whether pancreatic cancer, or, even 
more preferable, high-grade precursor lesions can be 
detected earlier in a potentially still curable stage [4]. By 
identifying additional genetic risk factors (genetic modi-
fiers) in these individuals, surveillance could possibly be 
more individualized.
In recent years, genome-wide association studies 
(GWAS) have identified several common risk variants 
associated with pancreatic cancer [5–7]. In this study, we 
genotyped a selected number of these variants (SNPs) in 
a unique cohort of p16-Leiden mutation carriers with and 
without pancreatic cancer. We hypothesized that these 
SNPs might modify the risk of pancreatic cancer in these 
p16-Leiden mutation carriers.
Methods
Study population and DNA sample collection
For this case–control study, only proven carriers of the 
p16-Leiden germline mutation were included. From 
all Dutch p16-Leiden mutation carriers, DNA is stored 
in the Laboratory for Diagnostic Genome Analysis 
(LDGA) of the Leiden University Medical Center. All 
p16-Leiden germline mutation carriers diagnosed at the 
LDGA between the initiation of CDKN2A gene diag-
nostics at the LDGA in 1998 and January 1st 2014 were 
eligible for inclusion. Cases were defined as having been 
diagnosed with exocrine pancreatic cancer at the time 
of data collection; controls were at least 55  years old 
on January 1st 2014 or died beyond that age, and were 
not diagnosed with pancreatic cancer. Individuals who 
were younger than 55 years or died before this age were 
excluded from the control group. Medical records were 
obtained for each individual from the electronic hospi-
tal information system of the medical center where this 
individual initially received genetic counselling by a clini-
cal geneticist for CDKN2A gene diagnostics. Access to 
these medical records was granted for the (co)authors 
since they are clinical geneticists working in these medi-
cal centers. Additional follow up data was acquired from 
two ongoing pancreatic surveillance studies (a single-
center study at Leiden University Medical Center and a 
multi-center study at Erasmus MC University Medical 
Center Rotterdam) and from the Netherlands Founda-
tion for the Detection of Hereditary Tumours, a central 
registration institute for hereditary tumours (FAMMM, 
amongst others) in the Netherlands. This study was 
approved by the Ethics Committee of the Leiden Uni-
versity Medical Center, by issuing a declaration of no 
objection (#P14.148). This is an assessment of the study 
protocol on due diligence, that is, if it serves the codes 
of good practice and good conduct. It is not a formal ethi-
cal assessment, because the study does not fall within the 
scope of the Dutch law for medical research on human 
subjects; the medical records and the DNA were already 
available and the involved human subjects were not spe-
cifically recruited for the study and were not subjected to 
any actions. Therefore, no separate ethical assessment or 
approval was needed for the collection of data in the par-
ticipating medical centers.
SNP selection and genotyping
SNPs for genotyping in this cohort were selected from 
recent GWAS studies with large cohorts of sporadic pan-
creatic cancer patients [5–7]. Selection was based on 
significance of association with pancreatic cancer and 
reported odds ratios, as well as expected allele frequen-
cies. In the first place, SNPs with the largest odds ratios 
and smallest p-values were selected. Subsequently, only 
those SNPs with a relatively high minor allele frequency 
(MAF) were considered for genotyping, because of the 
limited sample size of the cohort. This would optimize 
the number of carriers of the minor allele and thereby 
augment the potential of reaching significance between 
subgroups. In order to test a relatively wide variety of 
genes, a maximum of two different SNPs per gene was 
maintained. All included individuals were genotyped for 
the selected SNPs using high-resolution DNA melting 
curve analysis [8]. Melting assays were performed with 
Lightscanner® (Biofire Defense Inc, Salt Lake City, UT, 
USA).
Statistical analysis
Given our relatively small sample size, we performed a 
power calculation with Bonferroni correction for multi-
ple testing prior to the study. Despite a calculated power 
of approximately 15%, we wanted to pursuit this small 
but tangible chance of finding a trend of association.
The frequencies of the risk alleles were computed and 
compared between cases and controls by calculating a 
SNP-specific allelic odds ratio, including the 95% confi-
dence interval. Additional p-values were calculated using 
a basic χ2 test and the Bonferroni correction for multi-
ple testing was applied. Therefore, a p value of less than 
0.007 was considered significant. All statistical analyses 
were performed using SPSS 20.0.0 (IBM Inc, Armonk, 
NY, USA).
Results
Patient characteristics (Table 1)
In total, 422 p16-Leiden germline mutation carriers were 
eligible for inclusion. Of these, 50 individuals (18 males, 
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36%) were diagnosed with pancreatic cancer, with a 
median age at diagnosis of 55 years (range 21–76 years), 
and could all be included in the case group. The remain-
ing 372 individuals were not diagnosed with pancre-
atic cancer, but 237 individuals were excluded from the 
control group because of not having reached the age 
of 55  years. The remaining control group consisted of 
135 individuals (50 males, 37%) with a median age of 
64 years (range 55–88 years). Thus, for this study a total 
of 185 p16-Leiden germline mutation carriers (from 88 
families) were included. A considerable number of indi-
viduals (98 of 185 [53%]) developed melanoma, and 37 
of 98 individuals with melanoma (38%) had multiple 
melanoma. In the case group, 24 of 50 individuals (48%) 
had a medical history of melanoma, and in the control 
group 74 of 135 individuals (55%) had a medical history 
of melanoma.
SNP genotyping and association with pancreatic cancer
A total of seven SNPs in five different genes were selected 
for genotyping. Table 2 shows the minor allele frequen-
cies of these SNPs in cases and controls, and the calcu-
lated association (allelic odds ratio and 95% confidence 
interval) with pancreatic cancer in our cohort of p16-Lei-
den germline mutation carriers. No significant asso-
ciation with pancreatic cancer was found for any of the 
seven SNPs.
Discussion
In this case–control study, we analysed seven pancreatic 
cancer-associated SNPs in a distinctively homogene-
ous cohort of 185 CDKN2A germline mutation carriers. 
That is, all cases with (n =  50) and all controls without 
(n =  135) pancreatic cancer carry the same p16-Leiden 
germline mutation. We hypothesized that (a subset of ) 
these SNPs would be associated with an increased pan-
creatic cancer risk in these individuals, and that genetic 
modifiers would explain, at least partially, the variabil-
ity in the occurrence of pancreatic cancer in p16-Leiden 
families. However, in our cohort, no significant asso-
ciation was found between the occurrence of pancreatic 
cancer and any of the seven SNPs.
Currently, research on genetic modifiers in CDKN2A 
mutation carriers is mainly focused on identifying low-risk 
variants that influence melanoma risk [9, 10]. To date, the 
MC1R gene, which is known to have a role in the skin pig-
mentation process, is the most important modifier gene 
identified so far [11, 12]. Penetrance of CDKN2A muta-
tions regarding melanoma risk is thus proven to be sub-
ject to low-risk genetic variants in other genes. Because 
of these encouraging results from previous studies, it can 
be expected that genetic variants could also be identified 
in CDKN2A mutation carriers which influence pancreatic 
cancer risk. It is however unlikely that these variants will 
be the same as those which influence melanoma risk, as 
Wu and colleagues demonstrated [13]. Other genetic vari-
ants should thus be considered when studying the risk of 
Table 1 Patient characteristics
p16-Leiden mutation carriers (N = 185)
Cases with pancreatic cancer (N = 50) Controls without pancreatic cancer (N = 135)
Median age in years (range) 55 (21–76) 64 (55–88)
Gender (m:f ) 18:32 50:88
Medical history of melanoma 24 (48%) 74 (55%)
Of which multiple 8/24 (33%) 29/74 (39%)
Table 2 Association of  seven selected SNPs with  pancre-
atic cancer in this study
a SNP reference (major/minor allele), chromosome location, gene.
Markera Minor Allele Fre-
quency
Allelic OR (95%  
CI)
Sign.  
(p value)
Cases Controls
rs2821367 (T, C)
1q32.1
NR5A2
0.37 0.38 1.0 (0.62–1.62) 1.00
rs7310409 (G, A)
12q24.31
HNF1A
0.35 0.39 0.87 (0.54–1.41) 0.57
rs735396 (A, G)
12q23.31
HNF1A
0.33 0.36 0.90 (0.55–1.47) 0.67
rs1805100 (G, A)
8q21.11
HNF4G
0.49 0.56 0.76 (0.48–1.21) 0.24
rs505922 (T, C)
9q34.2
ABO
0.30 0.33 0.87 (0.53–1.44) 0.59
rs657152 (G, T)
9q34.2
ABO
0.30 0.37 0.73 (0.44–1.20) 0.22
rs172310 (C, A)
7q36.3
SHH
0.43 0.39 1.18 (0.74–1.89) 0.49
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pancreatic cancer in CDKN2A mutation carriers. Yang 
et  al. [14] made a first attempt at this by sequencing the 
PALB2 gene in a small cohort of CDKN2A mutation car-
rying families with pancreatic cancer. The PALB2 gene 
(OMIM #610355) is one of the relatively few known high 
risk pancreatic cancer susceptibility genes associated with 
familial pancreatic cancer to date [15]. However, no patho-
genic mutations were identified in their study and also no 
association was found between SNPs in the PALB2 gene 
and the occurrence of pancreatic cancer.
The strength of this study is that our cohort of p16-Lei-
den mutation carriers is homogeneous regarding the 
type of mutation, and therefore relatively large in its 
kind. Yet, in order to study modifier effects in a cohort 
of individuals with a genetically inherited predisposition 
to cancer, a large sample size is important [16]. Because 
the p16-Leiden mutation is a rare mutation, an important 
limitation of this study is that sample size cannot easily 
be increased. Therefore, the lower age limit of the con-
trol group was set at 55 years (the mean age of pancreatic 
cancer in the case group). It is possible that individuals 
in the control group will develop pancreatic cancer in the 
future and this could have influenced the results. Possi-
bly, recalculations in the future, taking into account new 
clinical follow-up data of these individuals, could change 
the results significantly.
For this study, we selected seven promising pancreatic 
cancer-associated SNPs from the literature, based on 
reported odds ratios, p-values and reproducibility. The 
sample size limitation allowed us to test only a restricted 
number of SNPs and because of the limited sample size 
we chose for those with a relatively high minor allele fre-
quency. Our selection of seven SNPs is however only a 
subset of a much larger set of SNPs associated with pan-
creatic cancer and it is therefore still possible that these 
other SNPs do play a role in the pancreatic cancer risk 
in p16-Leiden germline mutation carriers (see [17] for 
an overview of associated SNPs). It is also possible that 
other, non-genetic, risk factors play a role in the variable 
pancreatic cancer phenotype. However, we do not have 
sufficient data available of these external risk factors in 
our studied mutation carriers. One of the most important 
non-genetic risk factors for developing pancreatic cancer 
is tobacco use, and even in CDKN2A germline mutation 
carriers it increases the risk for pancreatic cancer signifi-
cantly [18, 19].
Conclusions
This study aimed at identifying genetic modifiers that 
influence pancreatic cancer risk in a homogeneous 
cohort of Dutch p16-Leiden germline mutation carriers. 
Despite the fact that no significant association could be 
found for the seven tested pancreatic cancer-associated 
SNPs, it is still possible that these or other genetic modi-
fiers play a significant role in the individual pancreatic 
cancer risk in these individuals. The search for genetic 
modifiers for pancreatic cancer in p16-Leiden germline 
mutation carriers should therefore continue.
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